Comparative Pharmacology
Head-to-head clinical analysis: DIETHYLSTILBESTROL versus ESTRADIOL VALERATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIETHYLSTILBESTROL versus ESTRADIOL VALERATE.
DIETHYLSTILBESTROL vs ESTRADIOL VALERATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic nonsteroidal estrogen that binds to estrogen receptors (ERα/ERβ), activating estrogen-responsive gene transcription, leading to proliferation of estrogen-sensitive tissues.
Estradiol valerate is a prodrug of estradiol, a natural estrogen. Estrogens exert their effects by binding to estrogen receptors (ERα and ERβ), which act as transcription factors regulating gene expression. This leads to proliferation and growth of reproductive tissues, modulation of gonadotropin secretion, and effects on bone density, lipid metabolism, and other tissues.
0.5-2 mg orally once daily for palliative treatment of advanced prostate cancer; 5-15 mg orally once daily for prevention of postpartum breast engorgement.
1-2 mg orally once daily adjusted based on response; for hormone therapy, 5-20 mg intramuscularly every 4 weeks.
None Documented
None Documented
Clinical Note
moderateDiethylstilbestrol + Digoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDiethylstilbestrol + Digitoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDiethylstilbestrol + Deslanoside
"Diethylstilbestrol may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDiethylstilbestrol + Acetyldigitoxin
Terminal elimination half-life is approximately 24 hours (range 20-30 hours) in adults; prolonged in hepatic impairment.
Terminal elimination half-life is approximately 12-14 hours after intramuscular administration, allowing for weekly or biweekly dosing intervals.
Primarily renal (90% as glucuronide and sulfate conjugates), with less than 5% excreted unchanged in urine; biliary/fecal elimination accounts for about 10%.
Renal (approximately 50% as glucuronide and sulfate conjugates), biliary/fecal (approximately 30-40% as conjugates), with enterohepatic circulation.
Category C
Category D/X
Estrogen
Estrogen
"Diethylstilbestrol may decrease the cardiotoxic activities of Acetyldigitoxin."